報價延遲最少15分鐘:2026/04/22 20:06 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.03 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.42/-0.41
|
|
企業價值
1.00B
|
| 資產負債 |
|
每股賬面淨值
-0.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
81.39M
|
|
每股收益
0.07
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union. |
